Other studies demonstrate that miR-10b inhibits NK cells to recognize and attack to cancer cells through targeting MICB, a ligand expressed by tumor cells and recognized by NKG2D receptor of NK cells (Tsukerman et al., 2012). Here, MICB is linked to cancer.